Completed PHASE2 INTERVENTIONAL 1-arm NCT01994837

A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)

Sponsor: AbbVie

Conditions AML Acute Myelogenous Leukemia Acute Myeloid Leukemia

Interventions ABT-199

Updated 8 times since 2017 Last updated: May 2, 2018 Started: Nov 30, 2013 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01994837, this PHASE2 trial focuses on AML and Acute Myelogenous Leukemia and remains completed. Sponsored by AbbVie, it has been updated 8 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jul 2018 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Jul 2018 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Feb 2018 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Feb 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie
Genentech, Inc.

Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.